135 related articles for article (PubMed ID: 1539456)
1. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team.
Auerbach BS; Wilson ME; Lake AM; Deforest A; Steinhoff M; Halsey NA
Vaccine; 1992; 10(1):14-20. PubMed ID: 1539456
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
[TBL] [Abstract][Full Text] [Related]
4. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
5. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine.
Vanura H; Just M; Ambrosch F; Berger RM; Bogaerts H; Wynen J; Vandevoorde D; Wiedermann G
Vaccine; 1994; 12(3):210-4. PubMed ID: 8165852
[TBL] [Abstract][Full Text] [Related]
6. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants.
Anderson EL; Belshe RB; Bartram J
J Infect Dis; 1988 Apr; 157(4):731-7. PubMed ID: 2894399
[TBL] [Abstract][Full Text] [Related]
7. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
[TBL] [Abstract][Full Text] [Related]
8. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
9. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children.
Lewis K; Cherry JD; Holroyd HJ; Baker LR; Dudenhoeffer FE; Robinson RG
Am J Dis Child; 1986 Sep; 140(9):872-6. PubMed ID: 2874738
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
[TBL] [Abstract][Full Text] [Related]
11. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
[TBL] [Abstract][Full Text] [Related]
12. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
Miller E; Ashworth LA; Redhead K; Thornton C; Waight PA; Coleman T
Vaccine; 1997 Jan; 15(1):51-60. PubMed ID: 9041666
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
14. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
[TBL] [Abstract][Full Text] [Related]
15. Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules.
Just M; Kanra G; Bogaerts H; Berger R; Ceyhan M; Pêtre J
Dev Biol Stand; 1991; 73():275-83. PubMed ID: 1778319
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children.
Glode M; Joffe L; Reisinger K; Blatter M; Plotkin S; Watson B; Grossman L; Asmar B; Berry M; Starobin S
Pediatr Infect Dis J; 1992 Jul; 11(7):530-5. PubMed ID: 1528643
[TBL] [Abstract][Full Text] [Related]
17. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.
Kanra G; Ceyhan M; Vandevoorde D; Bogaerts H
Eur J Pediatr; 1993 Jun; 152(6):478-83. PubMed ID: 8335014
[TBL] [Abstract][Full Text] [Related]
18. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
20. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
